Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE1/PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2005-11-30

Study Completion Date

2009-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose is to evaluate safety and feasibility of the use of Rituximab as an adjunct to standard therapy (plasmapheresis + steroids) for patients with thrombotic thrombocytopenic purpura (TTP). This includes evaluating the rate and type of treatment failure.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

With this study we hope to evaluate safety and feasibility of the use of Rituximab as an adjunct to standard therapy (plasmapheresis + steroids) for patients with thrombotic thrombocytopenic purpura (TTP). This includes evaluating the rate and type of treatment failure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thrombotic Thrombocytopenic Purpura

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Thrombotic Thrombocytopenic Purpura TTP Hematology

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rituximab

Rituximab will be administered immediately after pheresis to minimize the amount of Rituximab that is removed by the subsequent days pheresis. The guidelines will be that 12 hours must elapse between the end of the first infusion of study drug and the next pheresis. Subsequent infusions would be weekly (plus or minus 2 days) with an attempt made to give study drug infusions after a pheresis that might be the last in a series, i.e. when no pheresis would be scheduled for at least the next day.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients will be included in the trial based on the following criteria:

* Patients must have TTP with platelet count \< 100,000/mL and microangiopathic hemolytic anemia which is defined as presence of at 3-10 fragmented red blood cells (schistocytes) per high power filed on the peripheral blood smear.
* Either gender, age 17 or older
* Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for six months after completion of treatment.
* TTP not related to underlying cancer, treatment of cancer or transplantation
* New onset TTP, or previously diagnosed TTP with an unmaintained remission for \>12 months.
* LDH \>2X upper limit of normal
* Prothrombin time (PT), partial thromboplastin time (PTT) normal
* Direct antiglobulin test (DAT) negative
* Subject has provided written informed consent
* Patients who have received up to 3 plasmapheresis.

Exclusion Criteria

Patients will be excluded from the trial based on the following criteria:

* A diagnosis of AIDS. Patients with HIV infection with absolute CD4 counts \>200/ul and no active, significant opportunistic infection are eligible
* Patients with a known hepatitis C infection (HCV) and/or with hepatitis B
* Patients receiving pheresis more than once a day
* Recent (within 1 year) bone marrow or hematopoietic stem cell transplant
* Patient is on calcineurin inhibitors, or is unable to come off them
* Acute or chronic disseminated intravascular coagulation (DIC), defined by D-dimers \>8mg/ml and fibrinogen \< 100 mg (0.1g)/dl
* A diagnosis of metastatic or non-metastatic malignancy other than basal cell carcinoma.
* Malignant hypertension (systolic blood pressure \[BP\] \> 200 mm Hg or a diastolic BP \> 130 mm Hg)
* Pregnancy (a negative serum pregnancy test should be performed for all women of childbearing potential within 7 days of treatment). Eligibility resumes 3 days after delivery
* Patients with family history of or a previous diagnosis of congenital TTP
* Patients with hemolytic uremic syndrome (HUS)
* Patients with sepsis

Minimum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

James B. Bussel

Professor of pediatrics

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

James B Bussel, M.D.

Role: PRINCIPAL_INVESTIGATOR

Weill Medical College of Cornell University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Weill Medical College of Cornell University/New York Presbyterian Hospital

New York, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0409007463

Identifier Type: -

Identifier Source: org_study_id